MarketPeel
Insider Trading Intelligence
RS

Russell Skibsted

PCSA
CHIEF FINANCIAL OFFICER · PROCESSA PHARMACEUTICALS, INC. · CIK 0001308105
FILING MIX · LIFETIME100%/0%
BUYS
14
SELLS
0
TOTAL VALUE
$41.7K
COMPANIES
2
ACTIVE SINCE
Sep 2020
HOLDINGS NOW
96,689
AVG SELL PX
TRADE KIND
SHOWING 14 / 14
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 11 pending
Forward-return performance of every backtestable P/S trade by Russell Skibsted, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+100.00%+7.89%+1.59%+6.30%+4.50%
14d3+66.67%+5.14%+3.91%+1.23%+6.88%
30d3+66.67%+1.37%+8.28%-3.63%-3.63%
60d3+33.33%-18.24%+3.71%-31.76%-31.76%
90d3(2 pending)+0.00%-26.34%+12.09%-38.43%-38.43%
180d3(3 pending)
1y3(3 pending)
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PCSA · 16,689 shares · as of Jun 30, 2026
0450,761901,5221,352,2831,803,04420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 14 buys / 0 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
3,277$1.93$6.3K16,689Jun 30, 2026Jul 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
2,654$2.22$5.9K13,412Jun 15, 2026Jun 16, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
2,292$2.57$5.9K10,758May 29, 2026Jun 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
1,984$2.97$5.9K8,466May 15, 2026May 19, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
2,190$2.69$5.9K6,498Apr 30, 2026May 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
1,984$2.97$5.9K4,308Apr 15, 2026Apr 17, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
2,324$2.54$5.9K2,324Mar 31, 2026Apr 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
108,000108,000Oct 1, 2025Oct 2, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
324,000324,000Oct 1, 2025Oct 2, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,775,0441,803,044Jul 24, 2025Jul 28, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
28,00028,000Jul 16, 2024Jul 18, 2024View →
RMTI
ROCKWELL MEDICAL, INC.
PURCHASEGRANT
Stock grant
80,00080,000Sep 9, 2022Sep 13, 2022View →
RMTI
ROCKWELL MEDICAL, INC.
PURCHASEGRANT
Stock grant
600,000600,000Sep 15, 2020Sep 15, 2020View →
RMTI
ROCKWELL MEDICAL, INC.
PURCHASEGRANT
Stock grant
150,000150,000Sep 15, 2020Sep 15, 2020View →
Other insiders · PCSA
Loading peer insiders…
About this filer
CIK 0001308105
ROLE
Chief Financial Officer
PRIMARY
PCSA
COMPANIES
2
ACTIVE SINCE
Sep 2020
MARKETPEEL · /INSIDER/0001308105DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback